Global Molecular Residual Disease Detection Supply, Demand and Key Producers, 2023-2029

Global Molecular Residual Disease Detection Supply, Demand and Key Producers, 2023-2029

The global Molecular Residual Disease Detection market size is expected to reach $ 12750 million by 2029, rising at a market growth of 14.9% CAGR during the forecast period (2023-2029).

Molecular residual lesions often refer to minimal residual lesions, which refer to a small number of cancer cells that remain in the body after cancer treatment (cancer cells that do not respond to treatment or are drug-resistant).

This report studies the global Molecular Residual Disease Detection demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Molecular Residual Disease Detection, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Molecular Residual Disease Detection that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Molecular Residual Disease Detection total market, 2018-2029, (USD Million)

Global Molecular Residual Disease Detection total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Molecular Residual Disease Detection total market, key domestic companies and share, (USD Million)

Global Molecular Residual Disease Detection revenue by player and market share 2018-2023, (USD Million)

Global Molecular Residual Disease Detection total market by Type, CAGR, 2018-2029, (USD Million)

Global Molecular Residual Disease Detection total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Molecular Residual Disease Detection market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical and Burning Rock Medicine, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Molecular Residual Disease Detection market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Molecular Residual Disease Detection Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Molecular Residual Disease Detection Market, Segmentation by Type
Tumor-informed Assays
Tumor-agnostic Assays

Global Molecular Residual Disease Detection Market, Segmentation by Application
Prognosis
Adjuvant Treatment Decision-Making
Surveillance for Postoperative Recurrence
Other

Companies Profiled:
Adaptive
Guardant Health
Invitae
Cergentis B.V
LexentBio
Natera
BGI
Zhiben Medical
Burning Rock Medicine
Huidu Medical
Zhenhe Technology
ExactSciences

Key Questions Answered

1. How big is the global Molecular Residual Disease Detection market?

2. What is the demand of the global Molecular Residual Disease Detection market?

3. What is the year over year growth of the global Molecular Residual Disease Detection market?

4. What is the total value of the global Molecular Residual Disease Detection market?

5. Who are the major players in the global Molecular Residual Disease Detection market?

6. What are the growth factors driving the market demand?